MicroRNA-205-5p regulates the chemotherapeutic resistance of hepatocellular carcinoma cells by targeting PTEN/JNK/ANXA3 pathway
Hepatocellular carcinoma (HCC) is a common malignant tumor of the digestive system, and patients with advanced HCC have a poor outlook, partly due to resistance to chemotherapeutic drugs. Previous studies have implicated microRNAs in the regulation of chemoresistance, and we have previously shown th...
Saved in:
Published in | American journal of translational research Vol. 9; no. 9; pp. 4300 - 4307 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
e-Century Publishing Corporation
01.01.2017
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Hepatocellular carcinoma (HCC) is a common malignant tumor of the digestive system, and patients with advanced HCC have a poor outlook, partly due to resistance to chemotherapeutic drugs. Previous studies have implicated microRNAs in the regulation of chemoresistance, and we have previously shown that microRNA (miR)-205-5p is down-regulated in multiple hepatoma cell lines. Here, we investigate whether miR-205-5p is involved in chemotherapeutic resistance in HCC. Expression of miR-205-5p was measured by real-time quantitative reverse transcription PCR and cell viability was determined using a CCK-8 cell viability assay. Expression of proteins in the PTEN/JNK/ANXA3 pathway were assessed via Western blotting. We found that miR-205-5p expression was down-regulated in all HCC cell lines investigated. In addition, miR-205-5p expression was upregulated by 5-fluorouracil (5-Fu) treatment in Bel-7402 (Bel) cells. Interestingly, miR-205-5p expression was increased in multidrug-resistant Bel-7402/5-Fu (Bel/Fu) cells, compared with Bel cells. We next demonstrated that sensitivity to 5-Fu was increased in Bel/Fu cells after treatment with a miR-205-5p inhibitor. Similarly, increased resistance to 5-Fu was observed in Bel cells after transfection with a miR-205-5p mimic. We injected nude mice with Bel/5-Fu cells to promote tumor growth, and found that co-treatment with a miR-205-5p antagomir and 5-Fu slowed tumor growth more than either treatment alone. Finally, we found that these effects were all associated with changes in the PTEN/JNK/ANXA3 pathway. In conclusion, inhibition of miR-205-5p may reverse chemotherapeutic resistance to 5-Fu, and this may occur via the PTEN/JNK/ANXA3 pathway. |
---|---|
AbstractList | Hepatocellular carcinoma (HCC) is a common malignant tumor of the digestive system, and patients with advanced HCC have a poor outlook, partly due to resistance to chemotherapeutic drugs. Previous studies have implicated microRNAs in the regulation of chemoresistance, and we have previously shown that microRNA (miR)-205-5p is down-regulated in multiple hepatoma cell lines. Here, we investigate whether miR-205-5p is involved in chemotherapeutic resistance in HCC. Expression of miR-205-5p was measured by real-time quantitative reverse transcription PCR and cell viability was determined using a CCK-8 cell viability assay. Expression of proteins in the PTEN/JNK/ANXA3 pathway were assessed via Western blotting. We found that miR-205-5p expression was down-regulated in all HCC cell lines investigated. In addition, miR-205-5p expression was upregulated by 5-fluorouracil (5-Fu) treatment in Bel-7402 (Bel) cells. Interestingly, miR-205-5p expression was increased in multidrug-resistant Bel-7402/5-Fu (Bel/Fu) cells, compared with Bel cells. We next demonstrated that sensitivity to 5-Fu was increased in Bel/Fu cells after treatment with a miR-205-5p inhibitor. Similarly, increased resistance to 5-Fu was observed in Bel cells after transfection with a miR-205-5p mimic. We injected nude mice with Bel/5-Fu cells to promote tumor growth, and found that co-treatment with a miR-205-5p antagomir and 5-Fu slowed tumor growth more than either treatment alone. Finally, we found that these effects were all associated with changes in the PTEN/JNK/ANXA3 pathway. In conclusion, inhibition of miR-205-5p may reverse chemotherapeutic resistance to 5-Fu, and this may occur via the PTEN/JNK/ANXA3 pathway. Hepatocellular carcinoma (HCC) is a common malignant tumor of the digestive system, and patients with advanced HCC have a poor outlook, partly due to resistance to chemotherapeutic drugs. Previous studies have implicated microRNAs in the regulation of chemoresistance, and we have previously shown that microRNA (miR)-205-5p is down-regulated in multiple hepatoma cell lines. Here, we investigate whether miR-205-5p is involved in chemotherapeutic resistance in HCC. Expression of miR-205-5p was measured by real-time quantitative reverse transcription PCR and cell viability was determined using a CCK-8 cell viability assay. Expression of proteins in the PTEN/JNK/ANXA3 pathway were assessed via Western blotting. We found that miR-205-5p expression was down-regulated in all HCC cell lines investigated. In addition, miR-205-5p expression was upregulated by 5-fluorouracil (5-Fu) treatment in Bel-7402 (Bel) cells. Interestingly, miR-205-5p expression was increased in multidrug-resistant Bel-7402/5-Fu (Bel/Fu) cells, compared with Bel cells. We next demonstrated that sensitivity to 5-Fu was increased in Bel/Fu cells after treatment with a miR-205-5p inhibitor. Similarly, increased resistance to 5-Fu was observed in Bel cells after transfection with a miR-205-5p mimic. We injected nude mice with Bel/5-Fu cells to promote tumor growth, and found that co-treatment with a miR-205-5p antagomir and 5-Fu slowed tumor growth more than either treatment alone. Finally, we found that these effects were all associated with changes in the PTEN/JNK/ANXA3 pathway. In conclusion, inhibition of miR-205-5p may reverse chemotherapeutic resistance to 5-Fu, and this may occur via the PTEN/JNK/ANXA3 pathway.Hepatocellular carcinoma (HCC) is a common malignant tumor of the digestive system, and patients with advanced HCC have a poor outlook, partly due to resistance to chemotherapeutic drugs. Previous studies have implicated microRNAs in the regulation of chemoresistance, and we have previously shown that microRNA (miR)-205-5p is down-regulated in multiple hepatoma cell lines. Here, we investigate whether miR-205-5p is involved in chemotherapeutic resistance in HCC. Expression of miR-205-5p was measured by real-time quantitative reverse transcription PCR and cell viability was determined using a CCK-8 cell viability assay. Expression of proteins in the PTEN/JNK/ANXA3 pathway were assessed via Western blotting. We found that miR-205-5p expression was down-regulated in all HCC cell lines investigated. In addition, miR-205-5p expression was upregulated by 5-fluorouracil (5-Fu) treatment in Bel-7402 (Bel) cells. Interestingly, miR-205-5p expression was increased in multidrug-resistant Bel-7402/5-Fu (Bel/Fu) cells, compared with Bel cells. We next demonstrated that sensitivity to 5-Fu was increased in Bel/Fu cells after treatment with a miR-205-5p inhibitor. Similarly, increased resistance to 5-Fu was observed in Bel cells after transfection with a miR-205-5p mimic. We injected nude mice with Bel/5-Fu cells to promote tumor growth, and found that co-treatment with a miR-205-5p antagomir and 5-Fu slowed tumor growth more than either treatment alone. Finally, we found that these effects were all associated with changes in the PTEN/JNK/ANXA3 pathway. In conclusion, inhibition of miR-205-5p may reverse chemotherapeutic resistance to 5-Fu, and this may occur via the PTEN/JNK/ANXA3 pathway. |
Author | Qu, Wei-Kun Ye, Ming-Liang Wang, Li-Ming Shao, Ping Fan, Rong Tian, Yu Sun, De-Guang Sui, Ji-Dong Gao, Zhen-Ming Wang, Cheng-Ye |
Author_xml | – sequence: 1 givenname: Ping surname: Shao fullname: Shao, Ping organization: Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The Second Affiliated Hospital of Dalian Medical UniversityDalian, China – sequence: 2 givenname: Wei-Kun surname: Qu fullname: Qu, Wei-Kun organization: Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The Second Affiliated Hospital of Dalian Medical UniversityDalian, China – sequence: 3 givenname: Cheng-Ye surname: Wang fullname: Wang, Cheng-Ye organization: Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The Second Affiliated Hospital of Dalian Medical UniversityDalian, China – sequence: 4 givenname: Yu surname: Tian fullname: Tian, Yu organization: Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The Second Affiliated Hospital of Dalian Medical UniversityDalian, China – sequence: 5 givenname: Ming-Liang surname: Ye fullname: Ye, Ming-Liang organization: Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of SciencesDalian, China – sequence: 6 givenname: De-Guang surname: Sun fullname: Sun, De-Guang organization: Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The Second Affiliated Hospital of Dalian Medical UniversityDalian, China – sequence: 7 givenname: Ji-Dong surname: Sui fullname: Sui, Ji-Dong organization: Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The Second Affiliated Hospital of Dalian Medical UniversityDalian, China – sequence: 8 givenname: Li-Ming surname: Wang fullname: Wang, Li-Ming organization: Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The Second Affiliated Hospital of Dalian Medical UniversityDalian, China – sequence: 9 givenname: Rong surname: Fan fullname: Fan, Rong organization: VIP Ward No. 2, The Second Affiliated Hospital of Dalian Medical UniversityDalian, China – sequence: 10 givenname: Zhen-Ming surname: Gao fullname: Gao, Zhen-Ming organization: Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The Second Affiliated Hospital of Dalian Medical UniversityDalian, China |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28979703$$D View this record in MEDLINE/PubMed |
BookMark | eNpVUEtLxDAQLqKoq_4FydFL2Ty2yfYiLOJ7XUUUvJVpdrKNtE1NUmVP_nUrPtDTfMx8D-YbJZuta3Ej2WX5RKRTNmGbf_BOMgrhmVKZ5ZJvJzt8mqtcUbGbvN9Y7d39YpZymqVZRzyu-hoiBhIrJLrCxg3AQ4d9tHo4BxsitBqJM6TCDqLTWNeDxhMNXtvWNUA-V4GUaxLBrzDadkXuHk4X46vF9Xi2eJoJMgirN1jvJ1sG6oAH33MveTw7fTi5SOe355cns3nacSljyjg3iuuJWiJkUgMFaqa5AGGmitIcuZwILBkzzJRSLalUOluiVEYzk-lSiL3k-Mu368sGlxrb6KEuOm8b8OvCgS3-X1pbFSv3WmSSc674YHD0beDdS48hFo0Nn29Ci64PxdC1kkwM7IF6-DfrN-SndfEBRAKDMQ |
ContentType | Journal Article |
Copyright | AJTR Copyright © 2017 2017 |
Copyright_xml | – notice: AJTR Copyright © 2017 2017 |
DBID | NPM 7X8 5PM |
DatabaseName | PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | PubMed MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1943-8141 |
EndPage | 4307 |
ExternalDocumentID | PMC5622272 28979703 |
Genre | Journal Article |
GroupedDBID | --- 23M 2WC 53G ADBBV AEGXH AENEX ALMA_UNASSIGNED_HOLDINGS BAWUL C1A DIK F5P GX1 HYE NPM OK1 OVT RNS RPM TR2 7X8 5PM |
ID | FETCH-LOGICAL-p266t-122f72c47dea56ca0a0f893a3f87009e2643eb11f1fb67d067c5de67fc1f5cb33 |
ISSN | 1943-8141 |
IngestDate | Thu Aug 21 14:12:28 EDT 2025 Fri Jul 11 16:48:28 EDT 2025 Mon Aug 18 08:05:16 EDT 2025 |
IsPeerReviewed | false |
IsScholarly | true |
Issue | 9 |
Keywords | PTEN MicroRNA-205 chemotherapeutic resistance hepatocellular carcinoma |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-p266t-122f72c47dea56ca0a0f893a3f87009e2643eb11f1fb67d067c5de67fc1f5cb33 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Equal contributors. |
PMID | 28979703 |
PQID | 1947613622 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5622272 proquest_miscellaneous_1947613622 pubmed_primary_28979703 |
PublicationCentury | 2000 |
PublicationDate | 2017-01-01 |
PublicationDateYYYYMMDD | 2017-01-01 |
PublicationDate_xml | – month: 01 year: 2017 text: 2017-01-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | American journal of translational research |
PublicationTitleAlternate | Am J Transl Res |
PublicationYear | 2017 |
Publisher | e-Century Publishing Corporation |
Publisher_xml | – name: e-Century Publishing Corporation |
References | 26095609 - Stem Cell Reports. 2015 Jul 14;5(1):45-59 19244118 - Cancer Res. 2009 Mar 15;69(6):2287-95 22189913 - J Cell Biochem. 2012 May;113(5):1671-80 21546262 - Crit Rev Oncol Hematol. 2012 Feb;81(2):103-22 24339740 - Neoplasia. 2013 Nov;15(11):1282-91 21454583 - J Biol Chem. 2011 May 13;286(19):16606-14 18199536 - Cancer Res. 2008 Jan 15;68(2):425-33 18546601 - Nat Protoc. 2008;3(6):1101-8 25220842 - Int J Cancer. 2015 Mar 1;136(5):E359-86 19135886 - Cell. 2009 Jan 9;136(1):26-36 25763354 - Front Oncol. 2015 Feb 16;5:24 21802841 - Cancer Lett. 2011 Nov 28;310(2):160-9 26807189 - Am J Transl Res. 2015 Nov 15;7(11):2433-41 16557279 - Nat Rev Cancer. 2006 Apr;6(4):259-69 27379838 - Leuk Res. 2016 Aug;47:172-7 24375474 - Mol Carcinog. 2015 Aug;54(8):598-607 16251533 - N Engl J Med. 2005 Oct 27;353(17):1768-71 21330408 - Cancer Res. 2011 Apr 1;71(7):2611-21 25544773 - Oncotarget. 2015 Feb 10;6(4):2302-14 20405329 - Ann Surg Oncol. 2010 May;17(5):1247-56 25973003 - Int J Clin Exp Pathol. 2015 Feb 01;8(2):1175-83 16929323 - Nat Rev Cancer. 2006 Sep;6(9):674-87 26711784 - Tumour Biol. 2016 Jun;37(6):8007-18 14744438 - Cell. 2004 Jan 23;116(2):281-97 25929864 - Curr Protein Pept Sci. 2015;16(4):301-9 24084898 - Oncol Rep. 2013 Dec;30(6):2897-902 24145123 - Mol Oncol. 2014 Feb;8(1):83-92 19238171 - Cell Res. 2009 Apr;19(4):439-48 19646254 - Mol Cancer. 2009 Jul 31;8:56 |
References_xml | – reference: 19244118 - Cancer Res. 2009 Mar 15;69(6):2287-95 – reference: 21546262 - Crit Rev Oncol Hematol. 2012 Feb;81(2):103-22 – reference: 22189913 - J Cell Biochem. 2012 May;113(5):1671-80 – reference: 21454583 - J Biol Chem. 2011 May 13;286(19):16606-14 – reference: 25973003 - Int J Clin Exp Pathol. 2015 Feb 01;8(2):1175-83 – reference: 26807189 - Am J Transl Res. 2015 Nov 15;7(11):2433-41 – reference: 25763354 - Front Oncol. 2015 Feb 16;5:24 – reference: 16929323 - Nat Rev Cancer. 2006 Sep;6(9):674-87 – reference: 21802841 - Cancer Lett. 2011 Nov 28;310(2):160-9 – reference: 18546601 - Nat Protoc. 2008;3(6):1101-8 – reference: 26095609 - Stem Cell Reports. 2015 Jul 14;5(1):45-59 – reference: 24145123 - Mol Oncol. 2014 Feb;8(1):83-92 – reference: 16557279 - Nat Rev Cancer. 2006 Apr;6(4):259-69 – reference: 14744438 - Cell. 2004 Jan 23;116(2):281-97 – reference: 24375474 - Mol Carcinog. 2015 Aug;54(8):598-607 – reference: 20405329 - Ann Surg Oncol. 2010 May;17(5):1247-56 – reference: 18199536 - Cancer Res. 2008 Jan 15;68(2):425-33 – reference: 24084898 - Oncol Rep. 2013 Dec;30(6):2897-902 – reference: 25929864 - Curr Protein Pept Sci. 2015;16(4):301-9 – reference: 16251533 - N Engl J Med. 2005 Oct 27;353(17):1768-71 – reference: 19238171 - Cell Res. 2009 Apr;19(4):439-48 – reference: 21330408 - Cancer Res. 2011 Apr 1;71(7):2611-21 – reference: 27379838 - Leuk Res. 2016 Aug;47:172-7 – reference: 26711784 - Tumour Biol. 2016 Jun;37(6):8007-18 – reference: 24339740 - Neoplasia. 2013 Nov;15(11):1282-91 – reference: 19646254 - Mol Cancer. 2009 Jul 31;8:56 – reference: 19135886 - Cell. 2009 Jan 9;136(1):26-36 – reference: 25220842 - Int J Cancer. 2015 Mar 1;136(5):E359-86 – reference: 25544773 - Oncotarget. 2015 Feb 10;6(4):2302-14 |
SSID | ssj0065962 |
Score | 2.2671807 |
Snippet | Hepatocellular carcinoma (HCC) is a common malignant tumor of the digestive system, and patients with advanced HCC have a poor outlook, partly due to... |
SourceID | pubmedcentral proquest pubmed |
SourceType | Open Access Repository Aggregation Database Index Database |
StartPage | 4300 |
SubjectTerms | Original |
Title | MicroRNA-205-5p regulates the chemotherapeutic resistance of hepatocellular carcinoma cells by targeting PTEN/JNK/ANXA3 pathway |
URI | https://www.ncbi.nlm.nih.gov/pubmed/28979703 https://www.proquest.com/docview/1947613622 https://pubmed.ncbi.nlm.nih.gov/PMC5622272 |
Volume | 9 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Pb9MwGLXKDogL4jdlgIzEbQpLYsdWjlU1NDE1qqAT3alyHJtWWtNoTYTYhf-Ev5XPTuK61Q6wS5Q6aRT5vfh7fvnyGaGPVAOosYDnm0U6oDlRQcqSOCgKBmpbSsqksQYmGTu_pF_myXww-ONlLTV1_kne3vldyX1QhTbA1Xwl-x_IuotCA-wDvrAFhGH7TxhPTDbd12wEt5sESXVy0y4sb6o2APoAx9r_vgoOb41aNI-ylYgVTLiNcW8zUaVZVKjcrMWJadpaWWqzxI2XMJ2dZWYx5-zC1F_I5iNiCrIuf4q9l8Lu7Y9XjqI2sfC6dxy70kLOgv62FNaqnfYB1FqwNu9PrYKLxjH3e2drj5eq_BFcOTbOVq2Be9X49kXED-wLFYzb4Orbbn0R556Zqh2bU0qMYxn5g3fqcTT1BmJKwtAL6vCT-wEDcKzWlhUw4eQpD8kuHrosxelkDOowjjmE-Ackor0X1MZ5ZtYtMrWkuwvcNUU5zLT1pMvsCXrczTnwqCXQUzRQ5TP0cNJlVTxHvw94hB2PMNAHH_II73iENxrv8wg7HmHLI5z_wo5H2PDoFFh0ajmEOw69QJefz2bj86BbmCOoQM_VQRTHmseS8kKJhEkRilCD7hVEw-gfpgpENgENEOlI54wXIIhkUijGtYx0InNCXqKjclOq1whTKgqY0sYq54xKrlJR8LBImcwlhXOLIfrQ9-oCBj5z56JUm2a7ADpw0KIA0BC9ant5UbUVWhY9JkPE9_rfnWCKqu8fKVdLW1y9Q_zNvf95jB7teP4WHdU3jXoHwrXO31v-_AU-nKcz |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=MicroRNA-205-5p+regulates+the+chemotherapeutic+resistance+of+hepatocellular+carcinoma+cells+by+targeting+PTEN%2FJNK%2FANXA3+pathway&rft.jtitle=American+journal+of+translational+research&rft.au=Shao%2C+Ping&rft.au=Qu%2C+Wei-Kun&rft.au=Wang%2C+Cheng-Ye&rft.au=Tian%2C+Yu&rft.date=2017-01-01&rft.pub=e-Century+Publishing+Corporation&rft.eissn=1943-8141&rft.volume=9&rft.issue=9&rft.spage=4300&rft.epage=4307&rft_id=info%3Apmid%2F28979703&rft.externalDocID=PMC5622272 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1943-8141&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1943-8141&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1943-8141&client=summon |